Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Beneficial Side Effects of Topiramate in Obese Patients Undergoing Total Joint Arthroplasty
NCT04613024 · Stanford University · EARLY_PHASE1 · withdrawn · last registry update 2025-04-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Not funded” | – | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CA2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-13Phase 3 first posted: Hospital de Clinicas de Porto Alegre, Furosemide 40 Milligrams. + Furosemide 40 Milligrams. (NCT07469722)
- 2026-03-12Also stopped (terminated): University of Iowa, Metformin + Orlistat (NCT01351753)
- 2026-01-30Results posted on the registry: University of Florida, Phentermine / Topiramate Oral Product + Citrate Salts, Allopurinol, Diet (NCT04621929)
- 2026-01-22Also stopped (terminated): Supernus Pharmaceuticals, Inc., SPN-538 + Placebo (NCT04050293)
- 2026-01-14Results posted on the registry: Novo Nordisk A/S, Semaglutide + Orlistat (NCT05579249)
- 2026-01-13Phase 3 first posted: Huons Co., Ltd., HUC3-637 + HUC3-637-R (NCT07335211)
- 2025-12-18Also stopped (withdrawn): Eurofarma Laboratorios S.A., ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg + ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg (NCT05209984)
- 2025-11-21Results posted on the registry: Supernus Pharmaceuticals, Inc., SPN-538 + Placebo (NCT04050293)
- 2025-10-31Results posted on the registry: University of Virginia, Low-Dose Topiramate + Placebo (NCT01182766)
- 2025-08-26Results posted on the registry: University of Miami, Latanoprost + Bimatoprost (NCT02390284)
- 2025-08-26Also stopped (terminated): University of Miami, Latanoprost + Bimatoprost (NCT02390284)
- 2025-08-08Results posted on the registry: Vrije Universiteit Brussel, Intravenous acetazolamide 500 mg OD + Intravenous bumetanide TID (NCT05411991)
- 2025-07-08Results posted on the registry: Mario Negri Institute for Pharmacological Research, Low dose carbamazepine + Standard dose carbamazepine (NCT03689114)
- 2025-05-31Also stopped (withdrawn): Janey Pratt, Topiramate + Phentermine (NCT04572217)
- 2025-05-23Results posted on the registry: University of Colorado, Denver, Phentermine + Immediate Release Topiramate (NCT04095104)
- 2025-04-02Results posted on the registry: Padagis LLC, Brinzolamide/brimonidine ophthalmic suspension + Simbrinza 0.2%/1% Ophthalmic Suspension (NCT04944290)
- 2025-04-01Also stopped (terminated): Universidad Peruana Cayetano Heredia, Acetazolamide + Dexamethasone (NCT02945527)
- 2025-03-20Results posted on the registry: Mayo Clinic, Placebo + Acetazolamide (NCT04679389)
- 2025-03-20Also stopped (terminated): Mayo Clinic, Placebo + Acetazolamide (NCT04679389)
- 2025-03-06Also stopped (terminated): Laboratorios Sophia S.A de C.V., PRO-122 + Timolol eye drops (NCT03193333)
- 2025-02-28Also stopped (terminated): VA Office of Research and Development, a drug against CA2 (NCT04581603)
- 2025-02-14Also stopped (terminated): Stadtspital Zürich, Furosemide + Metolazone (NCT05986773)
- 2025-02-14Also stopped (withdrawn): University of California, Los Angeles, Medical weight loss (NCT05812183)
- 2025-01-28Also stopped (suspended): University of Sao Paulo, Carbamazepine-Implant + Topiramate-Implant (NCT03307863)
- 2025-01-20Phase 3 first posted: Mansoura University, Dapagliflozin 10mg + Acetazolamide 500mg (NCT06783166)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision